Q-omics provides the consensus-scored IGFL4 profile across patient tissues and cancer cell-line models. IGFL4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, IGFL4 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, IGFL4 RNA expression shows 15,581 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, COAD, and THYM as cancer lineages where IGFL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGFL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGFL4 survival associations across molecular data types. IGFL4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGFL4 RNA expression–survival associations across cancer types. High IGFL4 expression shows unfavorable associations in KICH, MESO, KIRP and UVM, but favorable associations in BLCA and PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for IGFL4 RNA expression.
This table summarizes IGFL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGFL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGFL4 shows higher tumor expression in COAD, THCA, LUSC, LIHC, LUAD and STAD. The COAD box plot shows higher IGFL4 RNA expression in tumor versus normal tissue (log2 FC = +1.248, t-test p < 0.001).
This table shows molecular features associated with IGFL4 in patient tissues and cancer cell lines. In patient samples, IGFL4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGFL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
